NCT06891300
Understanding and Treating Suicidal Ideation With Ketamine
StatusRecruiting
PhasePhase 2/3
Primary completion (estimated)
At risk: Primary completion moved at least 4 months later.
See at-risk trials from The Royal's Institute of Mental Health Research
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 3 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 16 words
- Primary and study completion pushed from Oct 2026 to Mar 2027
- Secondary endpoints: details revised at 2 of 2 entries
- Study description expanded, about 3 words
- Notable Trial status: Not Yet Recruiting to Recruiting
- Primary and study completion dates: Sep 2026 to Oct 2026
- Start date changed from estimate of Mar 2025 to Apr 8, 2025
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Change in white matter microstructure from pre-treatment to post-treatment, assessed via MRI.
Timeframe: Pre-treatment (up to -48 hours) to post-treatment (24+/-6 hours)
Secondary (2)
Change in extracellular free water from pre-treatment to post-treatment, assessed via MRI.
Change in neurite density index from pre-treatment to post-treatment, assessed via MRI.
Arms and interventions
KetamineExperimental
Participants will undergo a total of four IV ketamine infusions (0.5 mg/kg infused over 40 minutes), administered twice weekly for two weeks.
Drugs: ketamine hydrochloride
Sites
1 site in 1 country
- Royal Ottawa Mental Health CentreOttawa, Ontario, Canada